vitamin D supplements
Dietary Supplement70 mcg/day (equal to 2800 IU) of cholecalciferol
NCT Number: NCT06451016
Introduction:
A deficit in vitamin D may be involved in the development and presentation of Graves' disease (GD). Lack of vitamin D and GD are linked to deteriorating quality of life (QoL) and weakening of the muscles. Our goal was to look at the possible advantages of vitamin D supplementation for the improvement of thyroid-related QoL and muscle function in GD patients, as well as the possible drawbacks of anti-thyroid drugs (ATD).
Methodology:
A multicenter randomized controlled experiment with single-blinding was carried out with 48 patients who had been diagnosed with Graves' illness. The participants were split into two groups n=24 patients in each group. In addition to standard ATD, Group A received either 70 μg (2800 IU) of vitamin D daily or a corresponding placebo. Investigator measured muscular function and isometric strength at baseline, three, and nine months.
Looking for future studies?
Notify Me18 year–40 year
All sexes
Interventional
Not applicable
Frontier Medical and Dental College, Abbottābād, KPK, Pakistan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
70 mcg/day (equal to 2800 IU) of cholecalciferol
Matching Placebo
Time frame: base line and after 3months
Hand Grip strength was measured using dynamometer
Frontier Medical and Dental College, Abbotabad
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05907668
Autoimmune Diseases, Endocrine System Diseases
Mainz, Germany
View Trial DetailsNCT02798965
Autoimmune Diseases, Endocrine System Diseases
Amiens, France
View Trial DetailsNCT05945784
Amyotrophic Lateral Sclerosis, Autoimmune Diseases
Pomona, California, United States
View Trial DetailsNCT04932135
Autoimmune Diseases, Endocrine System Diseases
Basel, Switzerland
View Trial Details